IRT Commandment #8
Thou Shall Protect The Blind
You can jeopardize the results of an entire study through inappropriate disclosure of participant treatment assignment.
That is not theoretical risk. It is an operational reality, and I have seen it live and in person
Most people understand the obvious unblinding risks. Fewer recognize how often unblinding happens indirectly, through combinations of data points, access patterns, or operational shortcuts.
Protecting the blind is not just a system feature. It is a discipline requiring forethought and execution.
Unblinding Is Not Always Obvious
Unblinding does not only occur when a treatment is clearly disclosed. It can happen when multiple data elements are combined and interpreted together.
Shipment patterns, flawed kit ID schemes, resupply timing, replacement logic, role-based access, and assignment patterns are all common paths to unintended disclosure Even when no single data point reveals treatment, a combination may.
That is why unblinding risk must be evaluated across the full operational workflow, not just at the field level.
A Special Responsibility for IRT Providers
IRT providers are in a unique position. They are one of the few partners who routinely operate across both blinded and unblinded domains at the sponsors, CROs, depots, and sites.
That creates special responsibility in system design, access control, reporting, and support processes. It also requires disciplined role separation and strict handling of sensitive data.
This is not just good practice. It is foundational to study integrity.
Sponsor Accountability
Sponsors also carry clear responsibility here. They must define, in precise terms:
What constitutes unblinding (feels obvious but you would be surprised at what I’ve seen)
Who is considered unblinded
When unblinded data may be accessed
When, how, and to whom unblinded data may be distributed
This sounds obvious, but modern trial designs add layers of complexity that did not exist in the early IVRS era.
Adaptive designs, supply optimization, integrated platforms, and expanded data flows all increase the number of ways the blind can be compromised if definitions and controls are not explicit.
A Brief Word About Aggregate Data…
I’ll tease this for a future column. Even a study that is open label may restrict access to treatment assignment beyond an individual patient. Aggregate data may drive independent analysis and bias in an ongoing study, but I digress. A fight for another day.
The Takeaway
The blind is not protected by configuration alone. It is protected by definition, process, access control, and discipline.
Treat the blind as a study asset that requires continuous protection, not a checkbox at go live.